- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05977127
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly (HVaNa)
Respiratory tract infections, e.g. caused by SARS-CoV-2, disproportionately affect elderly. Vaccination has shown to be the most cost-effective approach to prevent infections. However, older adults often fail to induce a potent immune response to vaccines, as was also seen recently for COVID-19 mRNA vaccines. This is likely due to immune dysfunction as a consequence of aging. To potentiate a stronger immune response, vaccine administration into the papillary dermis (intradermal, ID) has been proposed as an alternative strategy to intramuscular (IM) administration.
Vaccination through the ID route has shown to be safe and equally or more effective than IM vaccination with a wide variety of vaccines. Recently, ID administration has been tested with two COVID-19 mRNA vaccines (Spikevax, Moderna and Comirnaty, Pfizer/BioNTech) in reduced (fractional) doses of the standard IM dose.
To ease ID administration and thereby facilitate the implementation of this route, silicon-based microneedles have been developed. These needles have shown to allow ID administration of the Spikevax vaccine with equal safety and immunogenicity profiles as the traditional Mantoux approach in young adults.
In the present study, we will investigate the immunogenicity of a 20 mcg dose of the COVID-19 mRNA Comirnaty vaccine through ID administration with silicon microneedles in elderly people (75 years and older), and compare this to immunogenicity of IM administration of a 20 mcg dose and a 30 mcg (standard IM) dose.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Nijmegen, Netherlands
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged ≥75 years at the moment of immunization.
- Healthy, determined by medical history and clinical judgement of the investigator. Participants with a pre-existing illness that is stable, defined as disease not requiring significant change in therapy or hospitalisation during the 6 weeks before enrolment and not expected to require any intervention during the study, can be included.
- Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures.
- Willing to postpone their regular COVID-19 vaccination upon invitation by the Municipal Health Service or general practitioner until at least four months after receiving the intervention.
- Completed a primary series of COVID-19 vaccination.
- Capable and willing to give personal signed informed consent.
- Adequate understanding of the procedures of the study and agrees to abide strictly thereby.
- Fully conversant in the Dutch language.
- Agrees his/her general practitioner is informed about participation in the study.
- Agrees to provide access to information regarding their vaccination background.
- Agrees that the study physician and his/her delegates have access to their medical file at Radboudumc.
Exclusion Criteria:
- Medical or psychiatric condition that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study.
- No decision-making capacity.
- History of severe adverse reaction to a vaccine or to any component of the study intervention.
- Thrombose with thrombocytopenia syndrome after vaccination with a COVID-19 vaccine.
- Dermatological conditions that might interfere with the ID vaccination.
- Receipt of COVID-19 vaccination within 3 months before receiving the study intervention.
- Known or suspected immunodeficiency, as determined by medical history or medication use (inhalation corticosteroids are allowed).
- History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention.
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate IM injection.
- Participation in other studies involving other study interventions within 28 days prior and during 28 days after receiving the study intervention.
- Receipt of any other non-study vaccine within 28 days prior and after receiving the study intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intradermal vaccination with 20 mcg mRNA vaccine
Participants will receive a single dose of 20 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intradermal route using microneedles.
|
Administration of Comirnaty vaccine
|
Active Comparator: Intramuscular vaccination with 30 mcg mRNA vaccine
Participants will receive a single dose of 30 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intramuscular route.
|
Administration of Comirnaty vaccine
|
Active Comparator: Intramuscular vaccination with 20 mcg mRNA vaccine
Participants will receive a single dose of 20 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intramuscular route.
|
Administration of Comirnaty vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentrations of SARS-CoV-2-Spike protein specific IgG antibodies in serum for the different intervention groups
Time Frame: at 28 days after vaccination
|
at 28 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Titers of SARS-CoV-2 specific neutralising antibodies in serum of the different intervention groups
Time Frame: at 28 days after vaccination
|
at 28 days after vaccination
|
|
The percentage of participants with local and systemic adverse events
Time Frame: up to 28 days after vaccination
|
|
up to 28 days after vaccination
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentrations of SARS-CoV-2-Spike protein specific antibodies in serum and mucosal samples for the different intervention groups at various timepoints
Time Frame: Day 0, day 28 and month 4 after vaccination
|
Day 0, day 28 and month 4 after vaccination
|
|
Titers of SARS-CoV-2 specific neutralising antibodies in serum and mucosal samples of the different intervention groups at various timepoints
Time Frame: Day 0, day 28 and month 4 after vaccination
|
Day 0, day 28 and month 4 after vaccination
|
|
Changes in expression level of host genes
Time Frame: day 0 and day 1 after vaccination
|
day 0 and day 1 after vaccination
|
|
Cellular responses in blood and mucosal samples at various timepoints
Time Frame: Day 0, Day 28, month 4 after vaccination
|
e.g.
expressed as percentages of immune cell subsets or concentration of cytokines
|
Day 0, Day 28, month 4 after vaccination
|
Functional and phenotypic characterization of T cells at various timepoints after vaccination
Time Frame: Day 0, Day 28, month 4 after vaccination
|
e.g.
expressed as percentages of immune cell subsets or concentration of cytokines
|
Day 0, Day 28, month 4 after vaccination
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hans de Graaf, Stichting Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-503800-99-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Comirnaty
-
Medical University InnsbruckMedical University of Graz; Medical University of ViennaRecruiting
-
Jules Bordet InstituteRoche Pharma AGTerminated
-
Walvax Biotechnology Co., Ltd.Shanghai RNACure Biopharma Co., Ltd.Not yet recruiting
-
Sinocelltech Ltd.Not yet recruitingCOVID-19 | SARS-CoV-2 Infection
-
Sinocelltech Ltd.Not yet recruiting
-
Sinocelltech Ltd.Withdrawn
-
PfizerCompleted
-
Bavarian NordicCompletedCOVID-19 DiseaseUnited States, Denmark, Belgium
-
BioNTech SECompletedCOVID-19 | SARS-CoV-2 InfectionGermany
-
Walvax Biotechnology Co., Ltd.Shanghai RNACure Biopharma Co., Ltd.Not yet recruiting